Noa Biran, MD, is an Associate Professor of Medicine at Hackensack University Medical Center. She joined the Multiple Myeloma Division at John Theurer Cancer Center in September 2014.  The John Theurer Cancer Center Multiple Myeloma program is internationally recognized and cares for approximately 3000 patients with multiple myeloma per year on active therapy, and the translational and clinical research performed at the JTCC led to the FDA approval of nearly all of today’s therapies for multiple myeloma.

Dr. Biran previously served as Chief Fellow of Hematology and Medical Oncology at the  Icahn School of Medicine at Mount Sinai, New York.   Dr. Biran is actively involved in a high-volume clinical practice and is a clinical investigator focusing on patients with multiple myeloma and plasma cell dyscrasias. She is currently the principal investigator of investigator initiated as well as industry sponsored clinical studies.  Her primary research interest is in high-risk multiple myeloma as well as in harnessing the immune response in the advanced myeloma.  Her research efforts also focus on improving quality of life, evaluating for cognitive changes related to therapy and reducing time on therapy for patients with multiple myeloma. Her research has been presented at international and national conferences such as the American Society of Hematology, the American Society of Clinical Oncology,  and the Society of Hematologic Oncology. She is widely published in journals such as the Journal of Clinical Oncology,  Blood, The Lancet Hematology, Biology of Blood and Marrow Transplant, PLoS One, British Journal of Hematology, and the American Journal of Hematology.